Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Rises By 134.0%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 15th total of 5,300 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Barinthus Biotherapeutics Stock Up 1.5 %

Shares of Barinthus Biotherapeutics stock traded up $0.02 during trading hours on Thursday, reaching $1.04. 10,442 shares of the stock traded hands, compared to its average volume of 44,704. The company has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.24. The firm has a market capitalization of $41.64 million, a price-to-earnings ratio of -0.69 and a beta of -0.81. Barinthus Biotherapeutics has a one year low of $0.80 and a one year high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period in the previous year, the business posted ($0.37) earnings per share. Sell-side analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price target on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.